Treatment of membranous lupus nephritis

Seligman, 2002, Demographic differences in the development of lupus nephritis: a retrospective analysis, Am J Med, 112, 726, 10.1016/S0002-9343(02)01118-X Mittal, 2014, Rheumatological diseases and kidneys: a nephrologist's perspective, Int J Rheum Dis, 10.1111/1756-185X.12424 Bastian, 2002, Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis, Lupus, 11, 152, 10.1191/0961203302lu158oa Austin, 2005, Membranous lupus nephritis, Lupus, 14, 65, 10.1191/0961203305lu2062oa Chen, 2002, Clinicopathologic study in 152 patients with class V lupus nephritis, Chin J Nephrol, 18, 417 Schwartz, 1984, Clinical and pathological features of membranous glomerulonephritis of systemic lupus erythematosus, Am J Nephrol, 4, 301, 10.1159/000166828 Schwartz, 1989, Clinical outcome of three discrete histologic patterns of injury in severe lupus glomerulonephritis, Am J Kidney Dis, 13, 273, 10.1016/S0272-6386(89)80033-2 Adler, 1990, Lupus membranous glomerulonephritis: different prognostic subgroups obscured by imprecise histologic classifications, Mod Pathol, 3, 186 Pasquali, 1993, Lupus membranous nephropathy: long term outcome, Clin Nephrol, 39, 175 Radhakrishan, 1993, Lupus membranous nephropathy: course and prognosis in 50 patients (abstract), J Am Soc Nephrol, 4, 284 Mercadal, 2002, Factors affecting outcome and prognosis in membranous lupus nephropathy, Nephrol Dial Transplant, 17, 1771, 10.1093/ndt/17.10.1771 Mok, 2007, Risk and predictors of arterial thrombosis in lupus and non-lupus primary glomerulonephritis: a comparative study, Medicine (Baltimore), 86, 203, 10.1097/md.0b013e318123f888 Casciola-Rosen, 1994, Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes, J Exp Med, 179, 1317, 10.1084/jem.179.4.1317 Herrmann, 1998, Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus, Arthritis Rheum, 41, 1241, 10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H Burlingame, 1994, The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus, J Clin Invest, 94, 184, 10.1172/JCI117305 Urbonaviciute, 2008, Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE, J Exp Med, 205, 3007, 10.1084/jem.20081165 Nangaku, 2005, Cellular response to injury in membranous nephropathy, J Am Soc Nephrol, 16, 1195, 10.1681/ASN.2004121098 Churg, 1995, 151 Weening, 2004, The classification of glomerulonephritis in systemic lupus erythematosus revisited, J Am Soc Nephrol, 15, 241, 10.1097/01.ASN.0000108969.21691.5D Song, 2012, Differential diagnosis of lupus and primary membranous nephropathies by IgG subclass analysis, Clin J Am Soc Nephrol, 7, 1947, 10.2215/CJN.04800511 1992, Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Gruppo Italiano per lo Studio della Nefrite Lupica (GISNEL), Am J Kidney Dis, 19, 473, 10.1016/S0272-6386(12)80957-7 Appels, 1987, Long-term follow up of patients with lupus nephritis. A study based on the classification of the World Health Organization, Am J Med, 83, 877, 10.1016/0002-9343(87)90645-0 Jafar, 2001, Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data, Ann Intern Med, 135, 73, 10.7326/0003-4819-135-2-200107170-00007 Fessler, 2005, Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual, Arthritis Rheum, 52, 1473, 10.1002/art.21039 Pons-Estel, 2009, Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort, Arthritis Rheum, 61, 830, 10.1002/art.24538 Ruiz-Irastorza, 2006, Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus, Lupus, 15, 577, 10.1177/0961203306071872 Donadio, 1977, Membranous lupus nephropathy: a clinicopathologic study, Medicine, 56, 527, 10.1097/00005792-197711000-00007 Gonzalez-Dettoni, 1984, Membranous glomerulopathy in systemic lupus erythematosus, Adv Nephrol, 14, 347 Sloan, 1996, Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group, J Am Soc Nephrol, 7, 299, 10.1681/ASN.V72299 Nankivell, 2004, Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology, Transplantation, 78, 557, 10.1097/01.TP.0000128636.70499.6E Zhang, 2006, Randomized controlled trial of tacrolimus versus intravenous cyclophosphamide in the induction therapy of class V plus IV lupus nephritis, Chin Nephrol Dial Transplant, 15, 508 Radhakrishnan, 1994, Cyclosporine treatment of lupus membranous nephropathy, Clin Nephrol, 42, 147 Tam, 2001, Treatment of membranous lupus nephritis with prednisolone, azathioprine and cyclosporin A, Lupus, 10, 827, 10.1177/096120330101001113 Chan, 1999, Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression, Lupus, 8, 545, 10.1191/096120399678840837 Chen, 2011, Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial, Am J Kidney Dis, 57, 235, 10.1053/j.ajkd.2010.08.036 Wang, 2012, Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study, Lupus, 21, 1025, 10.1177/0961203312448105 Moroni, 1998, Treatment of membranous lupus nephritis, Am J Kidney Dis, 31, 681, 10.1053/ajkd.1998.v31.pm9531186 Austin, 2009, Randomized, controlled clinical trial of prednisone, cyclophosphamide and cyclosporine in lupus membranous nephropathy, J Am Soc Nephrol, 20, 901, 10.1681/ASN.2008060665 Mok, 1999, Lupus nephritis in Southern Chinese patients: clinicopathologic findings and long-term outcome, Am J Kidney Dis, 34, 315, 10.1016/S0272-6386(99)70361-6 Mok, 2009, Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine, Lupus, 18, 1091, 10.1177/0961203309106602 Kapitsinou, 2004, Lupus nephritis: treatment with mycophenolate mofetil, Rheumatology (Oxford), 43, 377, 10.1093/rheumatology/keh012 Spetie, 2004, Mycophenolate therapy of SLE membranous nephropathy, Kidney Int, 66, 2411, 10.1111/j.1523-1755.2004.66030.x Kasitanon, 2008, Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases, Lupus, 17, 40, 10.1177/0961203307085114 Appel, 2009, Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis, J Am Soc Nephrol, 20, 1103, 10.1681/ASN.2008101028 Radhakrishnan, 2010, Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis, Kidney Int, 77, 152, 10.1038/ki.2009.412 Swan, 2011, Systematic review and meta-analysis of immunosuppressant therapy clinical trials in membranous lupus nephritis, J Investig Med, 59, 246, 10.2310/JIM.0b013e318204c965 Jónsdóttir, 2011, Rituximab-treated membranous lupus nephritis: clinical outcome and effects on electron dense deposits, Ann Rheum Dis, 70, 1172, 10.1136/ard.2010.129288 Condon, 2013, Prospective observational single centre cohort study to evaluvate the effectiveness of treating lupus nephritis with rituximab and MMF but no oral steroids, Ann Rheum Dis, 72, 1280, 10.1136/annrheumdis-2012-202844 Jónsdóttir, 2013, Long-term follow-up in lupus nephritis patients treated with rituximab: clinical and histopathological response, Rheumatology, 52, 847, 10.1093/rheumatology/kes348 Liu, 2006, Mycophenolate mofetil versus intravenous pulse cyclophosphamide for class IV plus V lupus nephritis, Nephrol Dial Transplant, 15, 1 Bao, 2008, Successful treatment of class V+IV lupus nephritis with multitarget therapy, J Am Soc Nephrol, 19, 2001, 10.1681/ASN.2007121272 Hallegua, 2000, Cyclosporine for lupus membranous nephritis: experience with ten patients and review of the literature, Lupus, 9, 241, 10.1191/096120300680198935 Hu, 2003, Cyclosporine A in treatment of membranous lupus nephropathy, Chin Med J, 116, 1827 Ts, 2007, A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade, Lupus, 16, 46, 10.1177/0961203306073167 Szeto, 2008, Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis, Rheumatology, 47, 1678, 10.1093/rheumatology/ken335 Lu, 2008, Prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis, Lupus, 17, 622, 10.1177/0961203308089428 Karim, 2005, Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy, Rheumatology, 44, 1317, 10.1093/rheumatology/kei019 Jonsdottir, 2010, Clinical improvements in proliferative vs. membranous lupus nephritis following B-cell depletion: pooled data from two cohorts, Rheumatology, 49, 1502, 10.1093/rheumatology/keq055 2012, Kidney disease improving global outcomes: clinical practice guideline for glomerulonephritis, Kidney Int, 2, 221 Bertsias, 2012, Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for management of adult and paediatric lupus nephritis, Ann Rheum Dis, 71, 1771, 10.1136/annrheumdis-2012-201940 Hahn, 2012, American college of rheumatology guidelines for screening, treatment and management of lupus nephritis, Arthritis Care Res, 64, 797, 10.1002/acr.21664 Bono, 1999, The very long-term prognosis and complications of lupus nephritis and its treatment, QJM, 92, 211, 10.1093/qjmed/92.4.211 Donadio, 1995, Prognostic determinants in lupus nephritis: a long-term clinicopathologic study, Lupus, 4, 109, 10.1177/096120339500400206 Najafi, 2001, Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis, Kidney Int, 59, 2156, 10.1046/j.1523-1755.2001.00730.x Contreras, 2005, Factors associated with poor outcomes in patients with lupus nephritis, Lupus, 14, 890, 10.1191/0961203305lu2238oa Moroni, 1996, “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis, Kidney Int, 50, 2047, 10.1038/ki.1996.528 Sun, 2008, Long-term outcome of Chinese patients with membranous lupus nephropathy, Lupus, 17, 56, 10.1177/0961203307083443 Ayodele, 2010, Predictors of poor renal outcome in patients with biopsy-proven lupus nephritis, Nephrol (Carlton), 15, 482, 10.1111/j.1440-1797.2010.01290.x Okpechi, 2012, Outcome of patients with membranous lupus nephritis in Cape Town South Africa, Nephrol Dial Transplant, 27, 3509, 10.1093/ndt/gfs122 Contreras, 2004, Sequential therapies for proliferative lupus nephritis, N Engl J Med, 350, 971, 10.1056/NEJMoa031855 Moroni, 2012, Membranous nephropathy in systemic lupus erythematosus: long-term outcome and prognostic factors of 103 patients, Semin Arthritis Rheum, 41, 642, 10.1016/j.semarthrit.2011.08.002 Chen, 2008, Value of a complete or partial remission in severe lupus nephritis, Clin J Am Soc Nephrol, 3, 46, 10.2215/CJN.03280807 Ordonez, 1993, The increased risk of coronary heart disease associated with nephrotic syndrome, Kidney Int, 44, 638, 10.1038/ki.1993.292 Kono, 2014, Long-term outcome in Japanese patients with lupus nephritis, Lupus, 0, 1